- Home
- RNTX vs EQS Comparison
RNTX vs EQS Comparison
Compare RNTX & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- EQS
- Stock Information
- Founded
- RNTX 2001
- EQS 1991
- Country
- RNTX United States
- EQS United States
- Employees
- RNTX N/A
- EQS N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- EQS Finance Companies
- Sector
- RNTX Health Care
- EQS Finance
- Exchange
- RNTX Nasdaq
- EQS Nasdaq
- Market Cap
- RNTX 34.6M
- EQS 25.8M
- IPO Year
- RNTX N/A
- EQS N/A
- Fundamental
- Price
- RNTX $1.25
- EQS $1.89
- Analyst Decision
- RNTX Buy
- EQS
- Analyst Count
- RNTX 2
- EQS 0
- Target Price
- RNTX $10.00
- EQS N/A
- AVG Volume (30 Days)
- RNTX 2.6M
- EQS 4.8K
- Earning Date
- RNTX 11-14-2025
- EQS 01-01-0001
- Dividend Yield
- RNTX N/A
- EQS N/A
- EPS Growth
- RNTX N/A
- EQS N/A
- EPS
- RNTX N/A
- EQS N/A
- Revenue
- RNTX N/A
- EQS $1,355,000.00
- Revenue This Year
- RNTX N/A
- EQS N/A
- Revenue Next Year
- RNTX N/A
- EQS N/A
- P/E Ratio
- RNTX N/A
- EQS N/A
- Revenue Growth
- RNTX N/A
- EQS 60.35
- 52 Week Low
- RNTX $1.04
- EQS $0.74
- 52 Week High
- RNTX $3.50
- EQS $2.49
- Technical
- Relative Strength Index (RSI)
- RNTX 44.48
- EQS 46.64
- Support Level
- RNTX $1.15
- EQS $1.83
- Resistance Level
- RNTX $1.32
- EQS $1.97
- Average True Range (ATR)
- RNTX 0.20
- EQS 0.08
- MACD
- RNTX -0.04
- EQS 0.02
- Stochastic Oscillator
- RNTX 11.65
- EQS 51.72
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.